【レポートの概要（一部）】
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Application
08. Global Antibacterial Drugs Market
08.1 Introduction
08.2 Market Size and Forecast
08.3 Market Segmentation by Chemical Class
08.4 Market Segmentation by Drug Origin
09. Global Antifungal Drugs Market
09.1 Introduction
09.2 Market Size and Forecast
09.3 Market Segmentation by Chemical Class
09.4 Market Segmentation by Geography
09.4.1 Antifungal Drugs Market in the US
09.4.2 Antifungal Drugs Market in Europe
10. Global Antiviral Drugs Market
10.1 Introduction
10.2 Market Size and Forecast
10.3 Market Segmentation by Disease
10.4 Global Hepatitis C Drugs Market
10.4.1 Market Size and Forecast
10.4.2 Geographical Segmentation
10.5 Global Hepatitis B Drugs Market
10.5.1 Market Size and Forecast
10.6 Global HIV Drugs Market
10.6.1 Market Size and Forecast
11. Global Antiparasitic Drugs Market
11.1 Market Size and Forecast
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.2.1 Gilead Sciences
20.2.2 GlaxoSmithKline
20.2.3 Pfizer
20.2.4 F. Hoffmann-La Roche
20.2.5 Johnson & Johnson
20.2.6 Merck
20.3 Other Prominent Vendors
21. Key Vendor Analysis
21.1 F. Hoffmann La Roche
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Business Segmentation by Revenue 2012 and 2013
21.1.5 Geographical Segmentation by Revenue 2013
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 Gilead Sciences
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Geographical Segmentation by Revenue 2013
21.2.4 Recent Developments
21.2.5 SWOT Analysis
21.3 GlaxoSmithKline plc
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Pipeline Products
21.3.7 Business Strategy
21.3.8 Key Information
21.3.9 SWOT Analysis
21.4 Johnson & Johnson
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation by Revenue 2013
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Geographical Segmentation by Revenue 2013
21.4.6 Business Strategy
21.4.7 Recent Developments
21.4.8 SWOT Analysis
21.5 Merck
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2013
21.5.4 Business Segmentation by Revenue 2012 and 2013
21.5.5 Sales by Geography
21.5.6 Business Strategy
21.5.7 Key Developments
21.5.8 SWOT Analysis
21.6 Pfizer
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis
22. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Infectious Disease Treatment Market 2013-2018 (US$ million)
Exhibit 3: Global Infectious Disease Treatment Market Segmentation by Application
Exhibit 4: Global Infectious Disease Treatment Market Segmentation by Application 2013
Exhibit 5: Global Infectious Disease Treatment Market Segmentation by Application 2018
Exhibit 6: Global Infectious Disease Treatment Market Segmentation by Application 2013-2018 (US$ million)
Exhibit 7: Global Infectious Disease Treatment Market Segmentation by Application 2013-2018
Exhibit 8: Snapshot of Global Infectious Disease Treatment Market Segments 2013-2018
Exhibit 9: YoY Growth Rate of Global Infectious Disease Treatment Market Segments 2013-2018
Exhibit 10: Global Antibacterial Drugs Market: Key Drivers and Challenges
Exhibit 11: Global Antibacterial Drugs Market 2013-2018 (US$ million)
Exhibit 12: Global Antibacterial Drugs Market Segmentation by Chemical Class
Exhibit 13: Cephalosporin Segmentation by Generation of Drugs
Exhibit 14: Global Antibacterial Drugs Market Revenue Segmentation by Chemical Class 2013
Exhibit 15: Global Antibacterial Drugs Market Segmentation by Chemical Class in Volume 2013
Exhibit 16: Global Antibacterial Drugs Market Segmentation by Drug Origin
Exhibit 17: Global Antifungal Drugs Market: Key Drivers and Challenges
Exhibit 18: Global Antifungal Drugs Market 2013-2018 (US$ million)
Exhibit 19: Global Antifungal Drugs Market Segmentation by Chemical Class
Exhibit 20: Global Antifungal Drugs Market Segmentation by Chemical Class 2013
Exhibit 21: Global Antifungal Drugs Market by Geography Segmentation 2013
Exhibit 22: Antifungal Drugs Market in the US 2013-2018 (US$ million)
Exhibit 23: Antifungal Drugs Market in Europe 2013-2018 (US$ million)
Exhibit 24: Global Antiviral Drugs Market: Key Drivers and Challenges
Exhibit 25: Global Antiviral Drugs Market 2013-2018 (US$ million)
Exhibit 26: Global Antiviral Drugs Market Segmentation by Disease
Exhibit 27: Global Antiviral Drugs Market Segmentation by Disease 2013
Exhibit 28: Global Antiviral Drugs Market Segmentation by Disease 2018
Exhibit 29: Global Hepatitis C Drugs Market 2013-2018 (US$ million)
Exhibit 30: Global Hepatitis C Market by Geographical Segmentation 2013
Exhibit 31: Global Hepatitis B Drugs Market 2013-2018 (US$ million)
Exhibit 32: Global HIV Drugs Market 2013-2018 (US$ million)
Exhibit 33: Global Antiparasitic Drugs Market: Key Drivers and Challenges
Exhibit 34: Global Antiparasitic Drugs Market 2013-2018 (US$ million)
Exhibit 35: Global Infectious Disease Treatment Market by Geographical Segmentation 2013
Exhibit 36: Global Infectious Disease Treatment Market Share Analysis 2013
Exhibit 37: Revenue of Stribild 2012-2013 (US$ million)
Exhibit 38: Revenue of Truvada 2011-2013 (US$ million)
Exhibit 39: Revenue of Emtriva 2011-2013 (US$ million)
Exhibit 40: Revenue of Atripla 2011-2013 (US$ million)
Exhibit 41: Revenue of Complera/Eviplera 2011-2013 (US$ million)
Exhibit 42: Revenue of Viread 2011-2013 (US$ million)
Exhibit 43: Revenue of Hepsera 2011-2013 (US$ million)
Exhibit 44: Revenue of AmBisome 2011-2013 (US$ million)
Exhibit 45: Gilead Sciences: Percentage Share of Key Antiviral Drugs 2013
Exhibit 46: Share of Key Antiviral Drugs in Gilead Sciences’ Revenue 2013
Exhibit 47: Gilead Sciences: Percentage Share of Key Anti-infective Drugs 2011-2013
Exhibit 48: Gilead Sciences: Drug-wise Sales Comparison of Key Anti-infective Drugs 2011-2013
Exhibit 49: Gilead Sciences: Revenue Trend of Key Anti-infective Drugs 2011-2013
Exhibit 50: Gilead Sciences’ Key Anti-infective Drugs 2011-2013
Exhibit 51: Share of GlaxoSmithKline’s Anti-infective Segment 2013
Exhibit 52: GlaxoSmithKline’s Key Antiviral Drugs Portfolio
Exhibit 53: Share of Key Antiviral Drugs in GlaxoSmithKline’s Antiviral Drugs Segment 2013
Exhibit 54: Geography-wise Segmentation of GlaxoSmithKline’s Antiviral Drugs Segment 2013
Exhibit 55: Geography-wise Segmentation of GlaxoSmithKline’s Key Anti-viral Drugs 2013
Exhibit 56: Geography-wise Segmentation of GlaxoSmithKline’s Key Anti-viral Drugs 2013 (US$ million)
Exhibit 57: GlaxoSmithKline’s Key Antibacterial Drugs Portfolio
Exhibit 58: Share of Augmentin in GlaxoSmithKline’s Antibacterial Drugs Segment Revenue 2013
Exhibit 59: Region-wise Segmentation of GlaxoSmithKline’s Antibacterial Drugs 2013 (US$ million)
Exhibit 60: Geography-wise Segmentation of GlaxoSmithKline’s Antibacterial Drugs 2013
Exhibit 61: Geography-wise Segmentation of GlaxoSmithKline’s Antibacterial Drugs Segment 2013
Exhibit 62: GlaxoSmithKline’s Key Anti HIV Drugs Portfolio (ViiV Healthcare)
Exhibit 63: Geography-wise Segmentation of GlaxoSmithKline’s Key Anti HIV Drugs 2013
Exhibit 64: Geography-wise Segmentation of GlaxoSmithKline’s Key Anti HIV Drugs 2013 (US$ million)
Exhibit 65: Geography-wise Segmentation GlaxoSmithKline’s Anti HIV Drugs Segment 2013
Exhibit 66: Pfizer’s Key Anti-infective Drugs Portfolio
Exhibit 67: Pfizer’s Key Anti-infective Drug Sales 2011-2013
Exhibit 68: Share of F. Hoffmann-La Roche’s Key Anti-infective Drugs 2013
Exhibit 69: Geography-wise Segmentation of Pegasys 2013
Exhibit 70: Geography-wise Segmentation of Tamiflu 2013
Exhibit 71: Share of Johnson & Johnson’s Key Anti-infective Drugs 2013
Exhibit 72: Share of Johnson & Johnson’s Anti-infective Drugs 2011-2013
Exhibit 73: Johnson & Johnson’s Anti-infective Drugs Sales 2011-2013 (US$ million)
Exhibit 74: Johnson & Johnson: Drug-wise Sales Comparison of Anti-infective Drugs 2011-2013
Exhibit 75: Merck’s Key Anti-infective Drugs Portfolio
Exhibit 76: Share of Merck’s Key Anti-infective Drugs 2013
Exhibit 77: Share of Merck’s Key Anti-infective Drugs 2011-2013
Exhibit 78: Share of Merck’s Key Anti-infective Drugs 2011-2013 (US$ million)
Exhibit 79: Merck’s Drug-wise Sales Comparison of Key Anti-infective Drugs 2011-2013
Exhibit 80: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 81: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 82: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
Exhibit 83: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
Exhibit 84: Gilead Sciences: Geographical Segmentation by Revenue 2013
Exhibit 85: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 86: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 87: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 88: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 89: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 90: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 91: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 92: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 93: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 94: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 95: Pfizer Inc.: Business Segmentation
Exhibit 96: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 97: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 98: Pfizer Inc.: Revenue by Geography 2013
【レポート販売概要】
■ タイトル：世界の感染症治療薬市場：抗菌薬、抗ウイルス薬、抗真菌薬、抗寄生虫薬■ 英文：Global Infectious Disease Treatment Market 2014-2018
■ 発行日：2014年8月27日
■ 調査会社：Technavio
■ 商品コード：IRTNTR4063
■ 調査対象地域：グローバル
- 世界のイーサネット・バックホール装置市場動向（2012-2016）TechNavio's analysts forecast the Global Ethernet Backhaul Equipment market to grow (incremental) at a CAGR of 4.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the inexorable increase of mobile data. The Global Ethernet Backhaul Equipment market has also been witnessing the increasing investment in microwave backhaul. However, the delay in settin …
- ビックデータビジネス：経営者及びITリーダー向けの市場分析Most of business people are aware of market analysis and its importance to the business. The process of market analysis has been carried out over decades by highly paid experts who enhanced the business leaders’ knowledge of the market as an approach to improve the decision taking. Therefore, many business executives today believe that the Big Data technology is just a step to boost the business a …
- ヨーロッパの無菌包装市場About Aseptic Packaging Market in EuropeAseptic packaging consists of the filling of sterilized perishable items in pre-sterilized packages which is made of rigid and flexible plastics, metal, and other materials in a sterile environment. Aseptic packages ensure Extended Shelf Life (ESL) for the contents inside them and maintain their original texture, aroma, and other functional characteristics. …
- 血管ステントの世界市場2015-2022According to Stratistics MRC, the Global Vascular Stents Market is accounted for $8.21 billion in 2015 and is expected to reach $11.6 billion by 2022 growing at a CAGR of 5.18% from 2015 to 2022. Growing recognition for vascular stents and increasing occurrence of cardiovascular diseases are the major factors driving the market growth. Moreover, growing number of aging population, increasing occur …
- 自動車用スマートパーキングシステムの世界市場• Do you need smart parking systems market data?• Succinct smart parking systems market analysis? • Technological insight? • Clear competitor analysis? • Actionable business recommendations? Smart parking addresses parking issues, by making it easier for drivers to park their vehicles without wasting time and fuel. These systems make available real-time information about available parking spaces i …
- モバイルデータ及びアプリケーション：現状、展望、予測（Mobile Data & Applications: State of the Industry, Market Prospects, and Forecast 2013 – 2018）Mobile applications continue an explosive growth phase. There can be no doubt that several factors have led to this including data speed improvements from 3G to 4G, Apple’s pioneering and Google’s entry into the mobile OS arena, mobile application store expansion with open development, and the overall rapid penetration and usage of smartphones. We see the fourth generation (4G) of cellular via the …
- マイクロ熱電併給（マイクロCHP）の世界市場：エンジン、燃料電池The global micro CHP market is projected to grow at a CAGR of 14.2% during the forecast period, to reach USD 4.44 Billion by 2020. This growth is attributed to high energy efficiency, which is achieved by converting primary energy to heat and electricity at the end-user level. Micro CHP units have the potential to reduce CO2 emissions that reduces energy consumption as compared to the conventional …
- ワイヤーライン・サービス（Wireline Service）のグローバル市場（～2019）This report estimates the wireline services market in terms of value in $million. This has been broken down into component regions and further split into countries. Wireline services are required throughout the lifecycle of an oil and gas well. The ever increasing exploration and production activities across the globe and new areas of unconventional resources are the main drivers for the growth of …
- 長繊維熱可塑性プラスチックの世界市場予測（～2021）：樹脂種類別（ポリプロピレン、ポリアミド、ポリブチレンテレフタレート）、繊維種類別（ガラス繊維、炭素繊維）、用途別（自動車、電気・電子、一般消費財、スポーツ用品）、地域別“Long Fiber Thermoplastic (LFT) market projected to grow at a CAGR of 8.96% during the forecast period”The global Long Fiber Thermoplastic (LFT) market is projected to reach USD 4.26 billion by 2021, at a CAGR of 8.96% from 2016 to 2021. The key factor expected to drive the growth of the long fiber thermoplastic market is the increasing demand from the automotive industry, as long fiber thermoplas …
- バーチャル顧客構内設備（V-CPE）の世界市場予測（～2021年）The global Virtual CPE market is expected to grow from USD 486.5 Million in 2016 to USD 2,818.8 Million by 2021, at a CAGR of 42.1%. The main driving factors for the growth of the market include the growing demand for virtual or cloud-based solutions, benefit of cost optimization in maintaining hardware, and rising need for mobility. Among Virtual CPE solutions/tools, the application and controlle …
- 2014年戦略提言：ドイツの診断市場This new report from Venture Planning Group provides an overview of the German diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts for the following market segments: - Blood Banking - Cancer - Chemistry &nb …
- プロバイオティクスの世界市場予測（～2023年）“The probiotics market is projected to grow at a CAGR of 7.0%”The probiotics market is estimated to be valued at 45.64 billion in 2017, and projected to grow at a CAGR of 7.0%, to reach USD 64.02 billion by 2022. The market is primarily driven by factors such as growing awareness about the benefits of probiotics among customers, rising demand for nutrient-rich feed for animals, and increasing dema …
- 歯科用滅菌製品の世界市場：製品別（滅菌装置、超音波クリーナー、洗浄消毒器 、表面消毒剤、器具消毒剤、潤滑剤、洗浄液）、エンドユーザー別（病院、診療所、歯科技工所）、地域別予測Global Dental sterilization Market to reach USD 1.70 billion by 2025. Global Dental sterilization Market valued approximately USD 0.9 billion in 2016 is anticipated to grow with a healthy growth rate of more than 7% over the forecast period 2017-2025. Key factors which gives growth to the Dental sterilization market are increasing number of dental facilities and the growing pool of dental care per …
- 世界の企業向けソーシャルソフトウエア/ネットワーキング市場Enterprise Social Software (ESS) refers to a social networking layer on top of tradition collaborative tools, which enables content sharing, along with additional features such as document sharing, wikis, micro blogging, shared spaces and communities, amongst other business applications. These solutions provide enterprises with several advantages including increased transparency, better communicat …
- 世界の小売産業におけるワークフォース管理（WFM）ソフトウェア市場About Workforce Management Software Traditionally, workforce management was handled with the help of spreadsheets and time recording, which are time-consuming, can lead to non-productive idle times and poor customer services, and incur high operational costs. WFM software helps businesses to manage workforce scheduling, increase operational performance, and identify and solve workforce-related iss …
